InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (8 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
8
T+90 hit rate
0%
T+90 mean return
-9.2%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Lowdell Mark William, Directeur Scientifique. Director active across 1 company, notably Inmune Bio, Inc.. Cumulatively, 12 reports have been recorded. Breakdown: 1 buy · 8 sells. Total volume traded: €431k. Activity tracked since 7 July 2021. The latest transaction was disclosed on 2 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
7,211 shares@ US$1.40Common StockSEC:0001213900-26-075737:0
14,423 shares@ US$8.3215.6% of flowCommon StockSEC:0001213900-24-035721:0
Ideal exit: 14 Jan 2025 (T+270)
14,423 shares@ US$8.3215.6% of flowCommon StockSEC:0001213900-24-035472:0
23,590 shares@ US$8.430.44% mcap36.2% of flowCommon StockSEC:0001213900-22-014509:0
701 shares@ US$20.000.029% mcap2.4% of flowCommon StockSEC:0001213900-21-056740:0
701 shares@ US$20.001.7% of flowCommon StockSEC:0001213900-21-056740
2,357 shares@ US$20.000.099% mcap8.2% of flowCommon StockSEC:0001213900-21-055421:0
2,357 shares@ US$20.005.6% of flowCommon StockSEC:0001213900-21-055421
400 shares@ US$20.000.017% mcap1.4% of flowCommon StockSEC:0001213900-21-054642:0
400 shares@ US$20.001.0% of flowCommon StockSEC:0001213900-21-054642
5,850 shares@ US$20.0213.7% of flowCommon StockSEC:0001213900-21-036355
5,850 shares@ US$20.020.24% mcap19.9% of flowCommon StockSEC:0001213900-21-036355:0
12 of 12 declarations
About Lowdell Mark William
Mark William Lowdell is the Chief Scientific Officer at Inmune Bio, Inc. In this role, he is responsible for leading the company's research and development initiatives. Mark William Lowdell plays a key role in innovation and scientific advancement within the organization. His expertise in biotechnology and life sciences is essential for supporting Inmune Bio's research objectives. He collaborates with multidisciplinary teams to develop innovative therapeutic solutions.
